Research Experience & Area of Specialisation
Seven years in Pharmaceuticals industries such as
Glenmark Research Centre,
Dr.Reddys laboratories Ltd,
Mylan laboratories Ltd and
Suven Life Science with
5 years in Academics & In-vivo Pharmacology and Toxicology
Publications
Satiesh kumar R, Sugin Lal Jabaris. S, Ramesh K, Madhan B. Effect of type 1 collagen and its hydrolysed collagen peptides on the healing of mucosal ulcers in murine model of ulcerative colitis. Eur J Pharm Sci. 2016; In Press
Akila Kesavan P, Ilaiyaraja, Sofi Beaula W, Veena Kumari V, Sugin lal J, Arunkumar C, G. Anjana G, Satish Srinivas, Anita Suresh Kumar R, Ponraju D, Ganesh V. Tumor targeting using polyamidoamine dendrimer–cisplatin nanoparticles functionalized with diglycolamic acid and herceptin. Eur. J. Pharm. Biopharm. 2015 (16), 255-263
Sugin Lal Jabaris S, Sumathy H, Girish R, Sridhar N, Sukumar M, Saravana Babu C, Thanikachalam S, Mohan T. Phosphodiesterase- 4 inhibitors ameliorates cognitive deficits in deoxycorticosterone acetate induced hypertensive rats via cAMP/CREB signaling system. Brain Res. 2015; 1622, 279- 291
Sugin Lal Jabaris S, Sumathy H, Satiesh kumar R, Sridhar N, Thanikachalam S, Saravana Babu C. Eeffects of rolipram and roflumilast, phosphodiesterase 4 inhibitors, on hypertension-induced defects in memory function in rats. Eur. J. Pharmacol. 2015; 746(5), 138-147
Sugin Lal Jabaris S, Sumathy H, Sugumar M, Shiney Monica RA, Saravana Babu C, Thanikachalam S. Beneficial effects of phosphodiesterase-4 inhibitors on hypertension-induced defects in memory function in rats. Alzheimer's & Dementia 2014; 10 (4), P469-P470
Satiesh kumar R, Sathiamurthi P, Sugin Lal Jabaris, Madhan B. Preparation and evaluation of mesalamine in situ rectal gel using collagen carrier: A novel therapeutic approach for treating ulcerative colitis. Eur J Pharm Sci. 2012; 48 (1-2), 104-110
Ramakrishna Nirogi, Sugin Lal Jabaris, Pradeep J, Renny A, Dhanalakshmi S, Abdul Rasheed M, Praveen Kumar Royapalley Venkatesh G. Corrigendum to “Antinociceptive activity of α4β2* neuronal nicotinic receptor agonist A-366833 in experimental models of neuropathic and inflammatory pain. [Eur. J. Pharmacol. 2011, 668, 155–162. Eur. J. Pharmacol. 2011,678 (1-3), P101
Pradeep J, Dhanalakshmi S, Sugin Lal Jabaris, Rajesh Babu R, Baburao K, Sampurna Mohanty S, Vishwottam K, Nageswararao M, Ramanatha S, Ganesh B, Ishtiyaque A, Venkat Reddy M, Ram Mohan G, Faheem MA, Anil Shinde, Amol D, Rambabu N, Ramakrishna Nirogi. SUVN-G1031, a novel selective H3 receptor antagonist in animal models of cognitive deficits. Alzheimer’s & Dementia. 2011, 7(4), S796
Arumugam K, Sugin Lal Jabaris. S, Pal M. Recent Advances on Phosphodiesterase-4 inhibitors for the Treatment of Asthmatic and Chronic Obstructive Pulmonary Disease: A Review. J. Med. Chem. 2008, 51, 5471-5489
.png)
.png)
.png)
.png)
.png)
.png)